Skip to main content

Table 3 The somatostatin levels calculated in the different groups.

From: The therapeutic effect of the neuropeptide hormone somatostatin on Schistosoma mansoni caused liver fibrosis

  Group 1 Group 2 Group 1 vs. Group 2
No SOM treatment Uninf.: 119.4 ± 11.99
Acute: 297.3 ± 37.24
p-value: 0.01**
Chronic: 206.1 ± 13.30 Uninf.: 119.4 ± 11.99
Chronic: 206.1 ± 13.30
p-value: 0.008**
Acute: 297.3 ± 37.24
Chronic: 206.1 ± 13.30
p-value: 0.06 (BL)
1 day SOM treatment Acute: 240.3 ± 21.30 Uninf.: 131.6 ± 19.34
Chronic: 226.3 ± 5.41
p-value: 0.01**
Acute: 240.3 ± 21.30
Chronic: 226.3 ± 5.41
p-value: 0.71 (NS)
2 day SOM treatment Uninf.: 136.9 ± 11.69
Acute: 234.2 ± 23.65
p-value: 0.008**
Acute (untreated): 297.3 ± 37.24
Acute (2d SOM): 234.2 ± 23.65
p-value: 0.28
Uninf.: 151.6 ± 41.45
Chronic: 247.9 ± 13.11
p-value: 0.11 (NS)
Chronic (untreated): 206.1 ± 13.30
Chronic (2d SOM): 247.9 ± 13.11
p-value: 0.06 (BL)
Uninf. (17 wks.): 136.9 ± 11.69
Uninf. (21 wks.): 151.6 ± 41.45
p-value: 0.9 (NS)
Acute: 234.2 ± 23.65
Chronic: 247.9 ± 13.11
p-value: 0.73 (NS)
  1. SOM: somatostatin; Uninf.: uninfected; Inf.: infected; Wks.: weeks;
  2. * Significant difference (p < 0.05); ** significant difference (p < 0.01); BL: borderline significant difference; NS: not significant difference